Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP)

  • 48 Accesses

  • 23 Citations

Summary

Forty-one previously treated patients with advanced Hodgkin's disease were treated with a combination chemotherapy regimen — ABVD (adriamycin, bleomycin, velbe/vincristine, imidazole carboxamide). Complete remission was achieved in three patients (7%), partial remission in 23 (56%), and no response in 15 patients (37%). The median survival of the group was 12 months from the start of therapy. Survival correlated with response to treatment. No apparent benefit resulted from giving more than six courses of therapy (3 months' treatment time). There was no serious haematological toxicity in patients without bone marrow disease, and bleomycin and adriamycin toxicity was not apparent clinically or at autopsy in the dosages employed in the regime. Alopoecia was very frequent.

The role for ABVD, other than as a primary induction regimen, appears to be in conjunction with other regimens in the induction of patients with adverse features at presentation or during induction; or in the salvage and palliation of patients who demonstrate a response but fail to achieve remission, either initially or at relapse, with MOPP (mustine, vincristine, procarbazine, and prednisolone) or MVPP (mustine, vinblastine, procarbazine and prednisolone).

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bonadonna, G., Zucali, R., Monjardins, S., et al.: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36, 252–259 (1975)

  2. 2.

    Bonadonna, G., Uslenghi, C., Zucali, R.: Recent trends in the medical treatment of Hodgkin's disease. Eur. J. Cancer 11, 251–266 (1975)

  3. 3.

    Bonadonna, G., Zucali, R. De Lena, M., Valagussa, P.: Combined chemotherapy (MOPP or ABVD) — radiotherapy approach in advanced Hodgkin's disease. Cancer Treat. Rep. 61, 769–777 (1977)

  4. 4.

    Bonadonna, G., Fossati, V., De Lena, M.: MOPP versus MOPP plus ABVD in Stage IV Hodgkin's disease. Proc. Am. Assoc. Cancer Res.—ASCO 19, 363 (1978)

  5. 5.

    Carbone, P. O., Kaplan, H. S., Musshoff, K., Smithers, D. W., Tubiana, M.: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 31, 1860–1861 (1971)

  6. 6.

    Case, D. C., Young, C. W., Nisca, L., Lee, B. J., III, Clarkson, B. D.: Eight-drug combination chemotherapy (MOPP and ABVD) and local radiotherapy for advanced Hodgkin's disease. Cancer Treat. Rep. 60, 1217–1223 (1976)

  7. 7.

    Case, D. C., Young, C. W., Lee, B. J., III: Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABVD). Cancer 39, 1382–1386 (1977)

  8. 8.

    Clamon, G. H., Corder, M. P.: ABVD treatment of MOPP failures in Hodgkin's disease. A reexamination of goals of salvage therapy. Cancer Treat. Rep. 62, 363–367 (1978)

  9. 9.

    De Vita, V. T., Canellos, G. P., Moxley, J. H., III: A decade of combination chemotherapy for advanced Hodgkin's disease. Cancer 30, 1495–1504 (1972)

  10. 10.

    Fisher, R. I., De Vita, V. T., Hubbard, S. M., Young, R. C.: Prolonged disease-free survival in Hodgkin's disease following reinduction with MOPP. Proc. Am. Assoc. Cancer Res.-ASCO 18, 318 (1977)

  11. 11.

    Kaplan, E. L., Meier, P.: Non-parametric estimations from incomplete observations. Am. Stat. Assoc. J. 53, 457–480 (1958)

  12. 12.

    Levi, J. A., Wiernik, P. H., Diggs, C. H.: Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med. Pediatr. Oncol. 3, 33–40 (1977)

  13. 13.

    Lokich, J. J., Frei, E., III, Jaffé, N., Tullis, J.: New multiple-agent chemotherapy (B-Dopa) for advanced Hodgkin's disease. Cancer 38, 667–671 (1976)

  14. 14.

    Lukes, R. J., Butler, J. J.: The pathology and nomenclature of Hodgkin's disease. Cancer Res. 26, 1063–1081 (1966)

  15. 15.

    Santoro, A., Monjardins, S., Bonadonna, G.: Treatment of Nitrogen mustard, Oncovin, procarbazine and prednisolone (MOPP)-resistand Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine. Proc. Am. Assoc. Cancer Res.-ASCO 19, 363 (1978)

  16. 16.

    Sutcliffe, S. B., Wrigley, P. F. M., Peto, J., et al.: MVPP chemotherapy regimen for advanced Hodgkin's disease. Br. Med. J. 1978 1, 679–683

  17. 17.

    Vincente, J., Cortes-Funes, H.: ABVD for the treatment of advanced resistant lymphoma. Proc. Am. Assoc. Cancer Res.-ASCO 17, 189 (1976)

  18. 18.

    Vinciguerra, V., Coleman, M., Jarowski, C. I., et al.: A new combination chemotherapy for resistant Hodgkin's disease. JAMA 237, 33–35 (1977)

Download references

Author information

Correspondence to S. B. Sutcliffe.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sutcliffe, S.B., Wrigley, P.F.M., Stansfeld, A.G. et al. Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP). Cancer Chemother. Pharmacol. 2, 209–213 (1979). https://doi.org/10.1007/BF00258297

Download citation

Keywords

  • Prednisolone
  • Vincristine
  • Bleomycin
  • Adriamycin
  • Haematological Toxicity